GHRP-2
Human observationalWADA prohibitedAlso known as: Pralmorelin
Community-reported ranges are anecdotal and not clinically validated. Evidence grade shown reflects the strength of available human data. Not a prescription. Legal status varies by country and changes over time; verify locally.
Overview
A growth-hormone-releasing peptide with genuine clinical pedigree — approved in Japan as the diagnostic agent pralmorelin. It releases more GH than GHRP-6 with less of the hunger effect, which is its niche in the community.
Mechanism
Ghrelin-receptor agonist stimulating GH release, with less appetite effect than GHRP-6.
Evidence
Human diagnostic use documents its GH release; physique outcomes haven't been formally trialled.
Community-reported information
Community reports vary. Anecdotal and unvalidated; general information only.
General information only, not tailored to you and not a recommendation. Some regions withhold this entirely.
Half-life
Short.
Storage
Refrigerate lyophilised and reconstituted.
Commonly reported side effects
- Water retention
- Raised cortisol/prolactin
Legal status by region
- USNot FDA-approved for general human use.
Legal status changes over time; verify locally before relying on this.